Indaptus Therapeutics (INDP) Stock in Focus on Dec. 24, 2025: $6M Financing, Leadership Reset, and the Dilution Question
Indaptus Therapeutics, Inc. (NASDAQ: INDP) is getting unusual attention heading into December 24, 2025, after a late-December SEC filing laid out a $6.0 million preferred-stock financing, a boardroom reshuffle, and a new co-CEO / chairman appointment—a mix that can ignite short-term trading interest while also forcing investors to re-run the long-term share-count math. SEC+1 The key tension is straightforward: the deal injects capital into a clinical-stage biotech that has been funding itself through repeated capital raises, but it also introduces a preferred security that—if shareholders approve conversion—could translate into up to 111 million common shares. In micro-cap land, that number
